A Polypill for Acute Coronary Syndrome

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Jun 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether combining three common heart medicines—aspirin, a blood thinner (like prasugrel or clopidogrel), and a cholesterol-lowering drug (a statin)—into one single pill, called a polypill, can help people recover better after a heart problem known as acute coronary syndrome (ACS). ACS happens when blood flow to the heart is suddenly blocked, and these medicines are usually prescribed afterward to prevent further heart issues. The idea is that taking one combined pill might make it easier for patients to take their medicines regularly, which could reduce the chances of future heart problems.

People who might join the trial are adults (18 years or older) who have recently been in the hospital for ACS and have had a procedure to open blocked heart arteries. They must be prescribed aspirin, a blood thinner, and a strong statin medicine when they leave the hospital. The study will not include those who need blood thinners for other reasons, have allergies to these medicines, or have health issues that might shorten their life within a year. Participants will be randomly assigned to take either the polypill or their usual separate medicines, and researchers will follow them to see how well the polypill works and how easy it is to use. This trial is still in the planning stages and not yet recruiting patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18
• • Hospitalization for acute coronary syndrome with percutaneous coronary intervention
• • Discharged on aspirin, prasugrel or clopidogrel, and a high-intensity statin
• Exclusion Criteria:
• • Current need for systemic anticoagulation
• • Contraindication to receive any components of the polypill
• • History of allergic reaction or intolerance to aspirin, prasugrel or clopidogrel, or rosuvastatin
• • Comorbidities that might be expected to limit lifespan within the 12-month study period
• • Increased risk of bleeding or planned urgent surgery that would necessitate use of DAPT for \< 12 months
• • Inability to provide written informed consent
• • Pregnancy